Patents Assigned to Plasma Technologies, LLC
-
Patent number: 11884702Abstract: Methods are provided for isolation of immunoglobulin G (IgG) from plasma, where IgG is initially fractioned by salt precipitation, followed by successive ion exchange steps in which IgG appears in unbound, flow-through fractions of the ion exchange steps. Some embodiments employ successive anion exchange steps. Other embodiments employ an anion exchange step followed by application of flow-through of the anion exchange step to a cation exchange step, with IgG collected in flow-through fractions from the cation exchange step. IgG is collected at high yield (typically about 75% or greater) and high purity. Avoidance of binding and elution from chromatography media simplifies processing and scale up without sacrificing IgG quality or yield.Type: GrantFiled: December 22, 2021Date of Patent: January 30, 2024Assignee: Plasma Technologies, LLCInventors: Eugene Zurlo, Dennis Curtin, Klaus Peter Radtke, Ryan Dorfman, Matthew Whelihan
-
Patent number: 11760778Abstract: Methods for isolating proteins from solution by precipitation and compositions generated thereby are provided. A nonvolatile precipitation agent is added to an aqueous protein solution at a low concentration. Water is then removed from the resulting solution until the precipitant and the protein content of the solution increase to a concentration that provides the desired segregation of proteins between supernatant and precipitate. Additional water can be removed from the supernatant to provide additional fractionation. Water can be removed by evaporation (e.g. under reduced pressure) and/or diafiltration.Type: GrantFiled: September 23, 2020Date of Patent: September 19, 2023Assignee: Plasma Technologies, LLCInventors: Eugene Zurlo, Dennis Curtin, Peter Radtke, Kurt L. Brillhart
-
Patent number: 11739117Abstract: Compositions of the inventive concept provide a therapeutic protein with less than 2% contamination by the therapeutic protein in denatured form. Such compositions provide enhanced specific activity and improved stability on storage and/or in serum than corresponding therapeutic protein preparations resulting from conventional isolation methods.Type: GrantFiled: October 10, 2020Date of Patent: August 29, 2023Assignee: Plasma Technologies, LLCInventors: Eugene Zurlo, Dennis Curtin, Peter Radtke, Kurt L. Brillhart
-
Patent number: 11732004Abstract: Compositions and methods are provided that simplify isolation of proteins of interest from serum or plasma. Finely divided silica or a similar lipid/lipoprotein binding solid is used in combination with a protein precipitating agent to generate a solution that includes the protein of interest and that can be applied to chromatography media without resulting in significant fouling of the media. The method is particularly suitable for isolation of immunoglobulin G.Type: GrantFiled: April 8, 2021Date of Patent: August 22, 2023Assignee: Plasma Technologies, LLCInventors: Eugene Zurlo, Dennis Curtin, Klaus Peter Radtke, Kurt L. Brillhart
-
Patent number: 11719690Abstract: A method of producing protein products including alpha-1-proteinase inhibitor, gamma globulin, albumin, and other proteins from plasma includes steps of: (1) adding a salt to the blood product to produce a first intermediate, wherein the salt comprises between 11-13 wt % of the first intermediate; (2) separating the first intermediate to produce a first supernatant and a first paste; (3) adding a salt to the first intermediate to produce a second intermediate, wherein the salt comprises between 21-23 wt % of the second intermediate; (4) separating the second intermediate to produce a second supernatant and a second paste; (5) separating a third intermediate from the second supernatant by affinity chromatography; and (6) separating the third intermediate by ion exchange chromatography to produce an eluate containing the protein product. Advantageously, the inventive methods are simple and produce alpha-1-proteinase inhibitor, gamma globulin, albumin, and other proteins in high yields.Type: GrantFiled: September 23, 2020Date of Patent: August 8, 2023Assignee: Plasma Technologies, LLCInventors: Eugene Zurlo, Dennis Curtin
-
Patent number: 11028125Abstract: Methods of producing multiple protein products from blood-based materials including alpha-1-proteinase inhibitor, gamma globulin, albumin, and other proteins are described herein. The inventive methods include steps of: salt fractionation, chromatography, ultrafiltration, diafiltration, solvent-detergent treatment, and sterile filtration. Advantageously, the inventive methods are simple and produce alpha-1-proteinase inhibitor, gamma globulin, albumin, and other proteins in high yields. The sequence of process steps can be selected to obtain multiple products from various in-process materials, such as supernatants, pastes, chromatography flow-though, and chromatography washes.Type: GrantFiled: August 10, 2017Date of Patent: June 8, 2021Assignee: Plasma Technologies, LLCInventors: Eugene Zurlo, David Peter Nowotnik, Charles Heldebrant, Dennis Curtin
-
Patent number: 10836790Abstract: Compositions of the inventive concept provide a therapeutic protein with less than 2% contamination by the therapeutic protein in denatured form. Such compositions provide enhanced specific activity and improved stability on storage and/or in serum than corresponding therapeutic protein preparations resulting from conventional isolation methods.Type: GrantFiled: January 10, 2020Date of Patent: November 17, 2020Assignee: Plasma Technologies, LLCInventors: Eugene Zurlo, Dennis Curtin, Peter Radtke, Kurt L. Brillhart
-
Patent number: 10815270Abstract: Methods for isolating proteins from solution by precipitation are provided. A nonvolatile precipitation agent is added to an aqueous protein solution at a low concentration. Water is then removed from the resulting solution until the precipitant and the protein content of the solution increase to a concentration that provides the desired segregation of proteins between supernatant and precipitate. Additional water can be removed from the supernatant to provide additional fractionation. Water can be removed by evaporation (e.g. under reduced pressure) and/or diafiltration.Type: GrantFiled: January 9, 2020Date of Patent: October 27, 2020Assignee: Plasma Technologies, LLCInventors: Eugene Zurlo, Dennis Curtin, Peter Radtke, Kurt L. Brillhart
-
Patent number: 10809247Abstract: A method of producing protein products including alpha-1-proteinase inhibitor, gamma globulin, albumin, and other proteins from plasma includes steps of: (1) adding a salt to the blood product to produce a first intermediate, wherein the salt comprises between 11-13 wt % of the first intermediate; (2) separating the first intermediate to produce a first supernatant and a first paste; (3) adding a salt to the first intermediate to produce a second intermediate, wherein the salt comprises between 21-23 wt % of the second intermediate; (4) separating the second intermediate to produce a second supernatant and a second paste; (5) separating a third intermediate from the second supernatant by affinity chromatography; and (6) separating the third intermediate by ion exchange chromatography to produce an eluate containing the protein product. Advantageously, the inventive methods are simple and produce alpha-1-proteinase inhibitor, gamma globulin, albumin, and other proteins in high yields.Type: GrantFiled: October 14, 2016Date of Patent: October 20, 2020Assignee: Plasma Technologies, LLCInventors: Eugene Zurlo, Dennis Curtin
-
Patent number: 8293242Abstract: The instant invention provides novel and effective methods of isolating alpha-1-antitrypsin from cryo-poor plasma and formulating it into therapeutic products. This invention achieves higher yields and a superior quality of alpha-1-antitrypsin. Alpha-1-antitrypsin is isolated from cryo-poor plasma, using one or more salts selected from a group comprising sodium citrate, sodium acetate, sodium gluconate, ammonium sulfate, sodium chloride, sodium sulfate and ammonium chloride in two fractionation steps, followed by diafiltration to remove those salts employed.Type: GrantFiled: December 20, 2010Date of Patent: October 23, 2012Assignee: Plasma Technologies, LLCInventors: Gene Zurlo, Dennis Curtin, Allan Louderback
-
Patent number: 7879331Abstract: An efficacious large-scale alcohol-free plasma fractionation production process which produces a high-yielding, non-denatured, double viral-inactivated intravenous human immune gamma globulin (IgG) product. The process employs sodium citrate in two initial fractionation steps, followed by diafiltration to remove sodium citrate.Type: GrantFiled: September 22, 2005Date of Patent: February 1, 2011Assignee: Plasma Technologies, LLCInventors: Eugene J. Zurlo, Dennis D. Curtin, Allan L. Louderback
-
Patent number: 7879332Abstract: An efficacious large-scale alcohol-free plasma fractionation production process which produces a high-yielding, non-denatured, double viral-inactivated intravenous human immune gamma globulin (IgG) product. The process employs one or more salts from a group of salts comprising sodium citrate, sodium acetate, sodium gluconate, ammonium sulfate, sodium chloride, sodium sulfate and ammonium chloride in two initial fractionation steps, followed by diafiltration to remove those salts employed. A process which employs alcohol via the process of the disclosed inventive method is also disclosed.Type: GrantFiled: February 21, 2006Date of Patent: February 1, 2011Assignee: Plasma Technologies, LLCInventors: Gene Zurlo, Dennis Curtin, Allan L. Louderback
-
Patent number: 6777862Abstract: An apparatus and method for thrusting plasma, utilizing a Hall thruster with segmented electrodes along the channel, which make the acceleration region as localized as possible. Also disclosed are methods of arranging the electrodes so as to minimize erosion and arcing. Also disclosed are methods of arranging the electrodes so as to produce a substantial reduction in plume divergence. The use of electrodes made of emissive material will reduce the radial potential drop within the channel, further decreasing the plume divergence. Also disclosed is a method of arranging and powering these electrodes so as to provide variable mode operation.Type: GrantFiled: April 13, 2001Date of Patent: August 17, 2004Assignee: General Plasma Technologies LLCInventors: Nathaniel J. Fisch, Yevgeny Raitses
-
Patent number: 6448721Abstract: An apparatus and method for thrusting plasma, utilizing a Hall thruster with a cylindrical geometry, wherein ions are accelerated in substantially the axial direction. The apparatus is suitable for operation at low power. It employs small size thruster components, including a ceramic channel, with the center pole piece of the conventional annular design thruster eliminated or greatly reduced. Efficient operation is accomplished through magnetic fields with a substantial radial component. The propellant gas is ionized at an optimal location in the thruster. A further improvement is accomplished by segmented electrodes, which produce localized voltage drops within the thruster at optimally prescribed locations. The apparatus differs from a conventional Hall thruster, which has an annular geometry, not well suited to scaling to small size, because the small size for an annular design has a great deal of surface area relative to the volume.Type: GrantFiled: April 13, 2001Date of Patent: September 10, 2002Assignee: General Plasma Technologies LLCInventors: Yevgeny Raitses, Nathaniel J. Fisch